株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

定量噴霧式吸入器:医療機器のパイプライン評価

Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 348463
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
定量噴霧式吸入器:医療機器のパイプライン評価 Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2017
出版日: 2017年06月01日 ページ情報: 英文 119 Pages
概要

当レポートでは、定量噴霧式吸入器のパイプライン製品について調査分析し、開発段階別の比較分析に焦点を当てて、パイプライン製品の開発に従事している主要企業、進行中の臨床試験に関する情報なども含めて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 定量噴霧式吸入器の概要

第3章 開発中の製品

  • 定量噴霧式吸入器 - パイプライン製品:開発段階別
  • 定量噴霧式吸入器 - パイプライン製品:地域別
  • 定量噴霧式吸入器 - パイプライン製品:規制別
  • 定量噴霧式吸入器 - パイプライン製品:承認予定日別
  • 定量噴霧式吸入器 - 進行中の臨床試験

第4章 定量噴霧式吸入器 - 開発中のパイプライン製品:企業別

  • 定量噴霧式吸入器企業 - パイプライン製品:開発段階別
  • 定量噴霧式吸入器 - パイプライン製品:開発段階別

第5章 定量噴霧式吸入器企業と製品の概要

  • Aerophase Inc.
  • Bang & Olufsen Medicom a/s
  • Bespak Europe Ltd.
  • Globe Medical Tech, Inc.
  • Lab Automate Technologies Inc.
  • Min USA LLC
  • Mylan N.V.
  • Novartis AG
  • SkyePharma Plc

第6章 定量噴霧式吸入器 - 最近の動向

第7章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's Medical Devices sector report, "Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Metered Dose Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Metered Dose Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Metered Dose Inhaler Devices Overview 6

3 Products under Development 7

  • 3.1 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development 7
  • 3.2 Metered Dose Inhaler Devices - Pipeline Products by Territory 8
  • 3.3 Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path 9
  • 3.4 Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date 10
  • 3.5 Metered Dose Inhaler Devices - Ongoing Clinical Trials 11

4 Metered Dose Inhaler Devices - Pipeline Products under Development by Companies 12

  • 4.1 Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development 12
  • 4.2 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development 13

5 Metered Dose Inhaler Devices Companies and Product Overview 14

  • 5.1 Aerophase Inc Company Overview 14
    • 5.1.1 Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 Circassia Pharmaceuticals Plc Company Overview 15
    • 5.2.1 Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 Globe Medical Tech Inc Company Overview 19
    • 5.3.1 Globe Medical Tech Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.4 Lab Automate Technologies Inc Company Overview 20
    • 5.4.1 Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.5 Medicom Innovation Partner a/s Company Overview 21
    • 5.5.1 Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.6 Min USA LLC Company Overview 22
    • 5.6.1 Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.7 Mylan NV Company Overview 23
    • 5.7.1 Mylan NV Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.8 Propeller Health Company Overview 24
    • 5.8.1 Propeller Health Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.9 Rensselaer Polytechnic Institute Company Overview 25
    • 5.9.1 Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.10 Vectura Group Plc Company Overview 26
    • 5.10.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.11 Verona Pharma Plc Company Overview 28
    • 5.11.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 28

6 Metered Dose Inhaler Devices- Recent Developments 29

  • 6.1 May 17, 2017: Teva Showcases Asthma Research at the 2017 American Thoracic Society International Conference 29
  • 6.2 May 10, 2017: Mylan Reports First Quarter 2017 Results 30
  • 6.3 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 32
  • 6.4 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 32
  • 6.5 May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 34
  • 6.6 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 35
  • 6.7 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 39
  • 6.8 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 40
  • 6.9 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 40
  • 6.10 Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 41
  • 6.11 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 42
  • 6.12 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 43
  • 6.13 Mar 06, 2017: Vectura Group: Board Change 44
  • 6.14 Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 45
  • 6.15 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 47
  • 6.16 Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products 48
  • 6.17 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 49
  • 6.18 Jan 26, 2017: Symbicort granted paediatric exclusivity in the US 51
  • 6.19 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 51
  • 6.20 Jan 26, 2017: Achievement of sales milestone for COPD products 52
  • 6.21 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 53
  • 6.22 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 60
  • 6.23 Jan 11, 2017: Vectura Group: Pre-close update 60
  • 6.24 Dec 21, 2016: Symbicort Maintenance And Reliever Therapy (SMART) now available for adolescents in the UK offering patient-adjusted asthma treatment 61
  • 6.25 Dec 14, 2016: Consort Medical: Directorate Change 63
  • 6.26 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 63
  • 6.27 Dec 01, 2016: Aptar Pharma Nears Completion Of Elastomer Component Capacity In North America 65
  • 6.28 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 66
  • 6.29 Nov 25, 2016: Consort Medical: CFO Appointment 67
  • 6.30 Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 67
  • 6.31 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 72
  • 6.32 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 79
  • 6.33 Sep 07, 2016: New Scale-Up and Commercial Supply Agreement 82
  • 6.34 Aug 17, 2016: Consort Medical Announces Directorate Change 82
  • 6.35 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 83
  • 6.36 Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses 86
  • 6.37 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 88
  • 6.38 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down 94
  • 6.39 Jul 04, 2016: Marco Filippini Appointed Vice Coordinator of the Italian Biosimilars Group 94
  • 6.40 Jun 16, 2016: Consort Medical Announces Final results For The Year Ended 30 April 2016 95
  • 6.41 Jun 10, 2016: Vectura Group announces Directorate Changes 104
  • 6.42 Jun 10, 2016: Simone Menne - new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance 104
  • 6.43 Jun 08, 2016: Merck Expands its Investment Fund Merck Ventures 105
  • 6.44 May 26, 2016: Vectura Group - Preliminary Results for twelve months ending 31 March 2016 105
  • 6.45 May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event 113
  • 6.46 May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 114

7 Appendix 116

  • 7.1 Methodology 116
  • 7.2 About GlobalData 119
  • 7.3 Contact Us 119
  • 7.4 Disclaimer 119

List of Tables

1.1 List of Tables

  • Table 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development 7
  • Table 2: Metered Dose Inhaler Devices - Pipeline Products by Territory 8
  • Table 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path 9

List of Figures

1.2 List of Figures

  • Figure 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development 7
  • Figure 2: Metered Dose Inhaler Devices - Pipeline Products by Territory 8
  • Figure 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path 9
  • Figure 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date 10
  • Figure 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials 11
Back to Top